" /> Vadacabtagene Leraleucel - CISMeF





Preferred Label : Vadacabtagene Leraleucel;

NCIt synonyms : Anti-CD19/CD28/zeta Modified CAR CD3 T Lymphocytes JCAR015;

NCIt definition : Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.;

NCIt note : Clinical trial NCT02973191 has been terminated due to incidence of neurotoxicity and related deaths. 04/18/2017;

UNII : A4O2H9W17Y;

Molecule name : JCAR015; JCAR 15; JCAR 015;

NCI Metathesaurus CUI : CL520442;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.